Medplus Health Services Ltd. · NSE:MEDPLUS
Medplus Health Services — Q4 FY2025 Earnings Presentation
28 slides from Medplus Health Services's earnings presentation, May 27, 2025
Slide 1: Exchange filing cover letter for earnings call presentation
MedPlus Health Services Limited May 27, 2025 The Listing Department The Listing Department BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Exchange Plaza, Dalal Street, Fort, Bandra Kurla Complex, Mumbai 400 001 Bandra (East), Mumbai – 400 051 BSE Scrip Code: 543427 NS
Slide 2: MedPlus Health Services Limited Q4 FY2025 Investor Presentation
MEDPLUS HEALTH SERVICES LIMITED Q4 FY2025 INVESTOR PRESENTATION May 2025
Slide 3: Safe Harbour
Safe Harbour This presentation and the accompanying slides (the “Presentation”), which have been prepared by MedPlus Health Services Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for
Slide 4: The MedPlus Story
The MedPlus Story Overview Marked presence of 19 years with network of 4,700+ Stores Spread across 13 states and 1 union territory Cluster based expansion strategy: ‘Continue 2nd Largest Pharma Retailer in the country deeper penetration vs. with pioneer in omni channel Wider reach’ Well curated SKU’
Slide 5: FY2025 Highlights
Results Update FY2025 Highlights ₹ 61,361m Revenue ₹ 14,954m Gross Margin • ₹ 5,112m increase over FY24 9.1% • 24.4% Gross Margin, increased by yoy 245 bps yoy • 5.0% increase in private label over FY24 305 Store Net Additions Stores > 12 months • 398 gross additions • 8.0% revenue growth over FY24
Slide 6: Q4 FY2025 Highlights (1/2)
Results Update Q4 FY2025 Highlights (1/2) ₹ 15,096m Revenue ₹ 4,010m Gross Margin • ₹ 191m increase over Q4FY24 1.3% • 26.6% GM%, increased by 150 bps yoy qoq and increased by 400 bps yoy • ₹ 518m decrease over Q3FY25 3.3% qoq • 8.0% increase in private label over Q4FY24 100 Store Net Additions Stor
Slide 7: Q4 FY2025 Highlights (2/2)
Results Update Q4 FY2025 Highlights (2/2) Revenue, ₹m Gross Margin Operating EBITDA EBITDA, ₹m 26.6% 5.3% 1,522 25.0% 5.1% 1,450 15,762 15,614 23.7% 22.6% 22.1% 4.7% 1,360 Consolidated 14,905 14,888 15,096 3.9% 1,163 1,025 2.9% 799 803 739 581 435 15,460 15,325 25.5% 5.1% 5.2% 1,488 24.0% 1,431 14,6
Slide 8: Pharmacy Retail is Most Attractive Segment of Indian Retail
Pharmacy Retail is Most Attractive Segment of Indian Retail Overview High Growth Profile Amongst Various Indian Growth Rate To Continue in Foreseeable Highly Replicable Model Retail Formats Future on Back of High Unorganized Salience Given Best in Class Return Metrics Avg Revenue per Sq.ft p.a (INR
Slide 9: Cluster Based Network Enables Profitable Omni-Channel Service
Cluster Based Network Enables Profitable Omni-Channel Service Overview Stores As On Mar-25 Strong Cluster Based Network Strong network of 4,712 stores across Metros, Tier-One, Tier-Two and beyond. 4,712 stores 2- hour delivery Ability to service 100% market – acute + chronic Online only players cann
Slide 10: Scale Allows A Large Private Label Basket: 1250+ SKUs
Scale Allows A Large Private Label Basket: 1250+ SKUs Overview Pharma Over 800 products covering Chronic, Acute, OTC & Other Pharmaceutical products Non-Pharma Over 450 products covering, packaged food, baked goods, dry goods, cleaning products, cosmetics and toiletries Q4FY25 8
Slide 11: Poised for Growth
Poised for Growth Overview Key Pillars Of Growth MedPlus has an established base of operations in 13 states and 1 union territory. Therefore, we will: Growth in existing clusters and • Further grow in cities where we have market leadership. Metro and Tier - One followed A develop new clusters by Tie
Slide 12: Stores Added In Last 12 Months
Results Update 305 Stores Added In Last 12 Months As On Mar-24 As On Dec-24 As On Mar-25 Presence 4,407 4,612 4,712 We are present in stores stores stores 13 states and 1 union territory. The key urban centers are: Bangalore, 14 584 16 640 19 665 Chennai, 20 34 39 Hyderabad, 160 170 174 556 549 559
Slide 13: Stores Added In Last Quarter
Results Update 100 Stores Added In Last Quarter Q4 FY25 Openings Q4 FY25 Closures Q4 FY25 Closure Reasons We opened 113 3.7 113 13 stores in Q4FY25. stores stores There were 13 4 closures 8.4 7 3 25 5 2 4 12 2 1.3 23 5 9 6 2 Relocation Franchisee withdrawn 19 4 7 Others Powered by Bing Powered by Bi
Slide 14: Store Network: 22% Less Than 2 Years Old
Results Update Store Network: 22% Less Than 2 Years Old Pharmacy: Count Pharmacy: Age Structure of Stores1 Stores 4.407 4,444 4,552 4,612 4,712 8% 13% 12% 11% 15% Openings 108 60 100 37 14% 4,500 174 Maintaining 16% 18% steady store 4,000 23% 26% openings 3,500 3,000 2,500 4,407 4,444 4,552 4,612 2,
Slide 15: Profitable Older Stores: 12+ Months
Results Update Profitable Older Stores: 12+ Months Store Level Revenue Growth1 Store Level EBITDA Margin Store Level Operating ROCE2,3 61.7% 59.2% 11.7% 11.5% 58.1% 11.0% 52.2% 9.8% 10.3% 10.2% 9.3% 46.1% 6.8% 4.4% -0.9% Q4FY24 Q1FY25 Q2FY25 Q3FY25 Q4FY25 Q4FY24 Q1FY25 Q2FY25 Q3FY25 Q4FY25 Q4FY24 Q1
Slide 16: Revenue Mix: Increasing Share Of Private Label
Results Update Revenue Mix: Increasing Share Of Private Label Revenue Mix: By Product Category Revenue Mix3: By Location of Stores 3.6% 3.5% 3.7% 3.1% 3.4% Product mix 6.7% 6.7% 12% 12% 12% 13% 13% 7.9% 8.3% 9.7% Trend of 8.5% 9.1% increasing share 10.5% 11.3% 13.6% from Private 11.4% 11.2% 23% 23%
Slide 17: Omni-channel: Profitable With Negligible Acquisition Costs
Results Update Omni-channel: Profitable With Negligible Acquisition Costs Channel Revenue Channel Delivery Pincodes1 and Delivery Hubs 880 875 8.0% 100% 873 Hubs 620 632 630 638 598 870 Home Delivery Omni-Channel 870 7.0% Our online 80% presence grows 860 6.0% 2,867 2,858 on the back of 2,709 2,591
Slide 18: Income Statement
Results Update Income Statement Snapshot of Income Statement, ₹m Q4FY25 vs. Q4FY25 vs. FY25 vs. Q4FY24 Q3FY25 Q4FY25 FY24 FY25 Q4FY24 (yoy) Q3FY25(qoq) FY24 (yoy) Revenue 14,905.0 15,614.5 15,096.1 1.3% -3.3% 56,248.6 61,360.5 9.1% Gross Margin 3,366.0 3,908.6 4,009.7 19.1% 2.6% 12,332.3 14,953.9 21
Slide 19: Income Statement: Business Segments
Results Update Income Statement: Business Segments Snapshot of Income Statement, ₹m Q3FY25 Q4FY25 FY25 Pharmacy Pharmacy Pharmacy Diagnostic Others Total Diagnostic Others Total Diagnostic Others Total Retail Retail Retail Revenue 15,325.4 274.7 14.4 15,614.5 14,797.6 280.8 17.7 15,096.1 60,211.8 1,
Slide 20: Income Statement: Ind AS Adjustments
Results Update Income Statement: Ind AS Adjustments Snapshot of Income Statement: Ind AS Adjustments, ₹m Q3FY25 Q4FY25 FY25 Ind AS Ind AS Ind AS Ind AS Ind AS Ind AS Reported Reported Reported Impact Adjusted Impact Adjusted Impact Adjusted Revenue 15,614.5 - 15,614.5 15,096.1 - 15,096.1 61,360.5 -
Slide 21: Operating EBITDA Deep Dive
Results Update Operating EBITDA Deep Dive Operating EBITDA Bridge: From 12+ Months Stores to Consolidated, ₹m 817 34 803 0 769 -34 -13 Operating 12+ Months < 12 Months Pre-Operative Pharmacy Diagnostics Others Consolidated EBITDA Stores Stores* * Includes all Franchisee stores Q4FY25 19
Slide 22: Balance Sheet
Results Update Balance Sheet Key Balance Sheet items, ₹m Mar-24 Dec-24 Mar-25 Assets PPE and CWIP 3,240.4 3,039.5 3,038.5 Inventories 13,402.3 12,930.2 13,451.0 Cash 1,701.8 4,030.3 4,422.6 Liabilities Trade payables 2,530.4 2,827.1 2,989.6 1. Cash includes cash, bank balances and bank deposits Q4FY
Slide 23: Capital Productivity
Results Update Capital Productivity Working Capital Cycle, days ROCE2: Operating EBIT/ Avg. Capital Employed NWC (days) 68 69 61 61 63 19.3% 18.7% Year 1 Stores 49 48 108 days 43 15.4% 41 40 inventory (on Year 1 stores 11.7% 40 38 37 revenue) 36 33 Stores Older Than 12 months 6.9% 21 43 days invento
Slide 24: Cash Management
Results Update Cash Management Cash Management, Q4FY25, ₹m 4,000 Operating Cash Flow 3,500 ₹ 1,074m 3,000 Free Cash Flow ₹ 270m 2,500 2,000 1,497 1,500 1,000 -296 -128 -167 500 31 301 -637 0 PBT+ Decrease Taxes Capex Payment Interest Increase D&A+ Int. in Working of lease received in cash of Lease C
Slide 25: Appendix
Appendix A. The Board of Directors and Key Managerial Personnel B. Glossary 23
Slide 26: The Board of Directors and Management Team
A. The Board of Directors and Management Team Appendix Mr. Gangadi Madhukar Reddy Dr. Cherukupalli Bhaskar Reddy Mr. Murali Sivaraman Ms. Aparna Surabhi Mr. Madhavan Ganesan Mr. Thyagarajan Muralidharan Chairman, Managing Director Whole Time Director Non-Executive Non-Executive Non-Executive Non-Exe
Slide 27: Glossary
B. Glossary Appendix Term Description Metro: Bengaluru, Chennai (and Avadi), Hyderabad, Kolkata (and Howrah), Mumbai (and Thane) City Categorization Tier One: Ahmednagar, Baramati, Kharagpur, Nagpur, Nashik, Panruti, Pune, Ranaghat, Vijayawada, Visakhapatnam (internal) Tier Two: Hundred and Twenty-N
Slide 28: MedPlus Health Services Limited Contact
MEDPLUS HEALTH SERVICES LIMITED Manoj Kumar Srivastava Company Secretary & Compliance Officer manoj.srivastava@medplusindia.com cs@medplusindia.com Website: www.medplusindia.com INVESTOR RELATIONS Tanushree Chaurasia ir@medplusindia.com MEDIA AND PRESS ENQUIRIES marketing@medplusindia.com Reg. Offic
MedPlus Health Services — Q4 FY2025 Earnings Presentation on 6ix